Bitopertin

Published

dm+d

Unassigned

New Medicines

Schizophrenia sub-optimally controlled symptoms, + antipsychotics

Information

Licence extension / variation
Roche
Roche

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Mar 15. Reported as discontinued for Schizophrenia in all regions. [1]

Category

Glycine transporter-1 (GlyT1) inhibitor, first in class
Incidence pf schizophrenia is approximately 15.2 per 100,000 person-years and prevalence of approximately 7.2 per 1,000 persons. Most commonly starts in adolescence and early 20s, and in young people aged 10-18 schizophrenia accounts for 24.5% of all psychiatric admissions. [6]
Schizophrenia sub-optimally controlled symptoms, + antipsychotics
Oral

Evidence based evaluations

26 June 2012NHSC